News

The alliance allows a technology transfer from PharmaCore to Albemarle, offering PharmaCore customers long term, higher volume capacity for their pharmaceutical projects. Albemarle’s custom manufacturing capabilities include a

RTS is expected to pay a minimum of $500,000. Hatch will join its Life Science division, which has successfully served the North American big pharma, biotech and academic

The mid-to-long-term vision that the company drew up in 2007, set the targets: ‘Establish a solid foundation for the domestic business’, ‘Expand the international business operation’ and ‘Enrich

McAllister said that the test results are automatically sent back to the patient’s medical record in AVImark and test charges are automatically added to the patient’s invoice. Once

The grant is expected to be administered through the Office of the National Coordinator for Health Information Technology and managed by Altarum. It is expected to create over

Dov believes that the contemplated $2m cash payment to shareholders represents approximately $0.015 per share of Dov common stock. If the transaction is consummated, it is anticipated that

Business Standard quoted Kamlesh Patel, chairman of IDMA, Gujarat State Board, saying: “Currently, nearly 60% of the net pharma production in the country, amounting to around INR250bn, is

The company said that all ten of these patients, at all sampling time points, were found to have systemic interferon alpha-2b levels below the lower limit of detection

The alliance is expected to leverage Ascentage’s expertise in structure-based small molecule design, lead optimisation and preclinical development with 3SBio’s proven drug development and commercialisation capabilities in China.